Vlad Coric, Biohaven CEO
March 22, 2023 11:20 AM EDT
Deals

Bio­haven grabs TYK2/JAK1 drug for $20M to start, $950M on the line — to go af­ter Parkin­son's

Paul Schloesser

Associate Editor

Bio­haven is bet­ting big on tar­get­ing brain dis­or­ders such as Parkin­son’s and po­ten­tial­ly Alzheimer’s.

The Con­necti­cut biotech an­nounced Wednes­day that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times